APA (7th ed.) Citation

Patakas, A., Li, B., Mehta, N. K., Meetze, K., Baeuerle, P. A., Michaelson, J. S., . . . London, T. B. CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Patakas, Agapitos, Bochong Li, Naveen K. Mehta, Kristan Meetze, Patrick A. Baeuerle, Jennifer S. Michaelson, Hannah M. Findlay, and Timothy B. London. CLN-978, a Novel Half-life Extended CD19/CD3/HSA-specific T Cell-engaging Antibody Construct with Potent Activity Against B-cell Malignancies with Low CD19 Expression. BMJ Publishing Group.

MLA (9th ed.) Citation

Patakas, Agapitos, et al. CLN-978, a Novel Half-life Extended CD19/CD3/HSA-specific T Cell-engaging Antibody Construct with Potent Activity Against B-cell Malignancies with Low CD19 Expression. BMJ Publishing Group.